To whom correspondence should be addressed 6-(p-dimethvlaminophenylazo)benzothiazole (6BT) is an unusually potent rat hepatocarcinogen, producing large malignant liver tumours after only 2-3 months of dietary administration in a riboflavin-deficient diet This azocarcinogen has been evaluated in a Big Blue™ F344 transgenic rat (lacl) gene mutation assay. In a reproduction of the early stages of the carcinogenesis bioassay of this agent, rats were maintained on a riboflavin-deficient diet and were given 10 consecutive daily doses of 6BT (10 mg/kg) by oral gavage. The animals were killed and the livers examined 11 days after the final dose. The livers of 6BTtreated rats showed evidence of hepatocellular hypertrophy in centrolobular areas, with some indication of an increased incidence of mitotic figures. An ~ 10-fold increase in the mutation frequency of DNA isolated from an aliquot of the combined liver homogenates of 6BT-treated rats was observed over that obtained from an equivalent aliquot from control animals. Examination of DNA samples isolated from the livers of individual animals confirmed that 6BT was mutagenic in Big Blue™ rat livers. These data extend the sensitivity of this transgenic assay to include azo hepatocarcinogens. The determination of mutation frequencies using pooled tissue samples represented a major resource-saving adaptation of the assay protocol in the present study; the general advantages and disadvantages of this practice are discussed.
Introduction
6-(p-dimethylaminophenylazo)benzothiazole (6BT) is an analogue of the reference rat liver carcinogen 4-dimethylaminoazobenzene (DAB, Butter Yellow; for structures see Figure 1 ). 6BT is reported to be a potent hepatocarcinogen when incorporated into a riboflavin-deficient diet and fed to rats (Brown and Sanchorawala, 1968) . Low riboflavin reduces azo-reductive cleavage of the molecule and thereby enhances the carcinogenic potency of most azocarcinogens (Brown and Sanchorawala, 1968) . The potent hepatocarcinogenicity of 6BT was confirmed in this laboratory when it was administered by oral gavage to Sprague-Dawley and Alderley Park rats maintained on a riboflavin-deficient diet (Elliott et al, 1983) . Genetic toxicity studies with 6BT have shown that it is strongly mutagenic to Salmonella typhimurium (Ashby et al., 1982) , that it is a strong inducer of unscheduled DNA synthesis (UDS) in an in vivo rat liver assay (Ashby et al., 1985) and that it gives a positive response using an in vivo rat liver micronucleus assay (Braithwaite and Ashby, 1988) .
As a part of our investigations into chemical hazard assessment, we are evaluating the use of transgenic mouse mutation assays based on the lacl [Big Blue™ (Kohler et al, 1990) ] and lacZ [Muta™ Mouse, (Gossen et al., 1989) ] gene inserts. Both assays have been successfully employed in studies involving either single or multiple administrations of compounds (Tinwell et al., 1994a,b; Ashby et al, 1994) . The recent availability of the Big Blue™ F344 transgenic rat (Dycaico et al, 1993a,b) offered the opportunity to investigate the mutagenic potential of 6BT in this system. It was decided to employ a multiple-dose protocol in order to reproduce the early stages of the carcinogenesis bioassays of 6BT conducted in this laboratory (Elliott et al, 1983) . These studies involved administration of daily oral doses of 6BT (10 mg/kg) for 2 months and resulted in a high incidence of hepatocellular carcinoma after 4 months (Elliott et al, 1983) . The present investigation describes mutagenesis studies on the liver of Big Blue™ F344 rats administered 10 daily doses of 6BT (10 mg/ kg by oral gavage) whilst being maintained on a riboflavindeficient diet. The pathology of the resultant livers is also described. Given that a mutagenic response was expected for the liver a novel test protocol was used involving assessment of the mutation frequency in pooled liver samples.
Materials and methods

Chemicals
The sample of 6BT was as described previously (Ashby et al, 1982) . The compound was dissolved in corn oil (Kraft-Wesson) to give a dosing volume of 10 ml/kg body weight.
Animals and dosing
Male Big Blue™ homozygous F344 rats (Dycaico et al., 1993a,b) were obtained from Stratagene (Taconic Farms, Germantown, NY, USA) and were maintained in a rabies quarantine facility in plastic cages and exposed to a 12 h light/12 h dark cycle as previously described for transgenic mice (Tinwell et al, 1994a) . Ten days prior to the start of dosing, the diet was changed to one containing low levels of nboflavin [SDS diet (Witham, Essex, UK); 2-3 mg riboflavin/kg; Elliott et al, 1983] . The animals were maintained on this diet for the rest of the study.
Each rat (age 4 months, body weight ~300 g) received 10 consecutive daily doses of either corn oil (10 ml/kg), or 6BT suspended in corn oil (10 mg/kg) by oral gavage. Eleven days after cessation of dosing the animals were killed by an overdose of anaesthetic (Fluothane; Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK) followed by cervical dislocation, and samples of liver removed. Portions of the caudate lobes from each rat were fixed in formal saline for the preparation of sections to be stained with haematoxylin and eosin for routine pathological examination. The left lateral lobe of each animal was cut into small pieces. One piece was immediately homogenized in douncing buffer whilst the rest were flash frozen in liquid nitrogen and stored at -70°C. The liver homogenates were combined for each experimental group entailing six individual control rats and seven individual 6BT-treated animals. The combined homogenates were well mixed and an aliquot removed for DNA extraction.
DNA isolation and packaging
Total genomic DNA was isolated by digestion of liver homogenates with protease K/RNase A followed by phenol:chloroform:isoamyl alcohol extractions, as described previously (Tinwell et al, 1994a) . The lad target gene was rescued from genomic DNA using a one tube packaging system (Stratagene; Tinwell et al., 1994a) . The resultant phage particles were absorbed onto SCS-8 Escherichia coli grown as described previously (Tinwell et al., 1994a) and lad mutations determined using 25X25 cm NZY agar plates containing X-Gal (Tinwell et al., 1994a) .
Results
Tissue pathology
Examination of haematoxylin/eosin stained sections showed that the livers of the 6BT-treated rats consistently exhibited hepatocellular hypertrophy of the centrolobular areas, which was usually accompanied by disruption of the sinusoidal architecture. Cells of a macrophage-type morphology containing moderate quantities of brown pigment within their cytoplasm were present within the sinusoids of the disrupted areas. Two of the seven 6BT-treated rats exhibited a slight increase in the number of mitotic figures compared with control livers. These two livers also showed the most marked pathological changes. However, there was no evidence of cellular necrosis in the livers of any of the treated animals. These effects indicate that the dose level of 6BT employed here, and for the cancer bioassays (Brown and Sanchorawala, 1968; Elliott et al, 1983) , was close to, or at, the maximum tolerated dose (MTD).
Mutation analysis
Clearly positive mutagenic responses were obtained in the livers of 6BT-treated rats ( Table I ). The responses observed in DNA extracted from combined homogenates was confirmed in studies on individual animals. The two individual 6BTtreated animals used in the confirmatory mutation analysis displayed the range of pathological responses observed: the first animal (animal 1 in Table I) showing moderate centrilobular hepatocellular hypertrophy with no mitotic figures per section. The second animal (animal 2 in Table I ) displayed marked hypertrophy with an average of nine mitotic figures per section being recorded. Packaging efficiencies of 20 000-30 000 p.f.u./ packaging were consistent with those obtained for the corresponding mouse assay (Tinwell et al, 1994a,b) .
Discussion
In the late 1960s, Brown and his colleagues described the synthesis and rat hepatocarcinogenicity of several series of heterocyclic ring analogues of the reference rat liver carcinogen DAB. Among the most potent carcinogens thereby discovered was the 6-benzthiazole analogue of DAB, 6BT (Figure 1 ).
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Dietary administration of this chemical to rats lead to the appearance of gross and lethal liver tumours within a period of ~2 months (Brown and Sanchorawala, 1968) . In earlier studies we confirmed this carcinogenic effect (Elliott et al., 1983) and established 6BT as an unusually potent mutagen to S.typhimurium (Ashby et al., 1982) and capable of inducing both UDS (Ashby et al., 1985) and micronuclei (MN; Braithwaite and Ashby, 1988) in the liver of rats exposed to it in vivo.
The recent extension of the lad transgenic mouse mutation assay (Kohler et al, 1990; Gossen et al, 1989) to the rat (Dycaico etal, 1993a,b) enabled us to confirm the mutagenicity of 6BT to the rat liver (Table I ). The ~ 10-fold increase in mutation frequency observed for the treated rat livers was, by definition, measured in viable hepatocytes 11 days after cessation of dosing. Therefore, such data may be more relevant to the carcinogenic process than are UDS data derived from liver cells removed from the test animals a few hours after dosing, and before it can be known if they would survive the genetic damage being measured. The present data therefore provide encouragement that transgenic rodent assays will have a role to play in the genetic hazard assessment of chemicals.
The dose level of 6BT selected for the present study (10 mg/kg via oral gavage for 10 days) is the same as that used in our earlier confirmatory carcinogenesis bioassay of 6BT (Elliott et al, 1983) . That bioassay dose level was itself designed to yield an equivalent daily intake of 6BT to that received by the rats on the original dietary carcinogenicity bioassay (0.03% 6BT in diet; Brown and Sanchorawala, 1968 ). The acute pathology study incorporated into the present experiment revealed that while this dose level of 6BT produced acute morphological changes in the liver, together with some mitotic activity, no evidence of liver cell necrosis was observed. This indicates that a sub-chronic MTD of 6BT was achieved, but not exceeded (see Ashby et al, 1996) . The mitotic activity observed in some of the treated livers probably indicated that such activity was occurring in all of the treated livers at some stage (Ashby et al, 1996) . Such activity probably contributed to the expression as mutations of the primary DNA damage induced in the liver by 6BT (Ashby et al, 1985; Braithwaite and Ashby, 1988) .
Given the previously defined activities of 6BT, a positive mutagenic response was expected for it in the rat liver. This assumption enabled us to employ pooled liver samples with a considerable saving of resources. The possibility that the positive response observed for the treated pooled livers was due to a jackpot mutation in one of the treated animals (Mirsalis etal, 1993; Golds worthy et al, 1994) was eliminated by evaluation of the mutation frequency in the liver of two individual treated animals (the chance of encountering two jackpots being remote). These confirmatory studies were con-ducted using relatively low numbers of plaque forming units (p.f.u.) because a jackpot mutation would have become apparent with the first packaging. In fact, much lower numbers of PFU would have sufficed for this phase of the experiments.
Given the success of the pooled tissue protocol in the present study, its more general use is worthy of consideration. It would be of obvious use in structure activity studies where a range of chemicals are to be compared for their relative mutagenic potency to a pre-determined target tissue. The precaution of eliminating jackpot mutations would have to be taken and knowledge of inter-animal variability would be sacrificed. Another situation in which the protocol would be of value is where the mutagenicity of a test agent is to be studied in a range of tissues. In such studies, identification of the most sensitive tissue could be achieved by using pooled tissue samples, with follow-up studies in that tissue if individual animal data are required. Further, given that one of the potential advantages of transgenic rodent mutation assays is that one is not limited to a single target tissue, the pooled tissue protocol may offer the chance to study a larger number of tissues, and thus, more adequately assess the mutagenic activity in vivo of a new test chemical. Set against these advantages is the possibility that the use of pooled tissues might obscure a weak mutagenic response occurring in only a proportion of the treated animals.
In situations where there is no prior indication of which tissue to select for study the investigator would have to decide whether it is better to have pooled data on a wide range of tissues, or individual animal data on an arbitrarily selected tissue(s). If one accepts that animal group sizes of five to seven are now generally recommended for transgenic mutation assays (Gorelick and Thompson, 1994) the polarized decision would be whether to have pooled tissue data on five to seven tissues or individual animal data on one tissue. This polarized choice assumes that investigators will operate with some budgetary restraints, nonetheless, the protocol used for each experiment should be accorded individual consideration. Under such circumstances a combination of pooled tissue analyses, coupled with more detailed studies in a single tissue, may be appropriate. These considerations are suggested to be relevant to the continuing debate on transgenic mutation assay protocols (Mirsalis, 1993; Gorelick and Thompson, 1994; Ashby and Liegibel, 1994) and to the derivation of regulatory protocols for these assays.
